FGFR2/3-Altered Intrahepatic Cholangiocarcinoma: A Distinct Clinicopathologic and Molecular Subtype Associated with Improved Disease-Specific Survival
Modern Pathology · 2026-12 · 39 (12) · 101094
DOI: 10.1016/j.modpat.2026.101094 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Pathology, 2026-12. Verfasst von Wen-Yu Hsiao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Gastrointestinal and Liver Pathology, Emory University School of Medicine, Atlanta, Georgia. Die Arbeit nennt 61 Literaturangaben.
Abstract (Originalsprache)
Intrahepatic cholangiocarcinoma (iCCA) is an aggressive neoplasm with a poor prognosis. Fibroblast growth factor receptor (FGFR) has emerged as a therapeutic target; however, the clinicopathologic, molecular, and prognostic features of FGFR-altered iCCAs remain incompletely defined. Thus, a 5-year retrospective study of genomically profiled iCCAs using dual whole-exome and whole-transcriptome sequencing, stratified by FGFR2/3 alteration status, was performed to examine their clinicopathologic characteristics, biomarker expression, molecular profile, and prognostic significance on overall (OS), metastasis-free (MFS), progression-free (PFS), and disease-specific survival (DSS). Ninety iCCAs (25 [27.8%] FGFR2/3-altered and 65 [72.2%] FGFR2/3-wild-type) were identified. FGFR2/3-altered iCCAs encompassed FGFR2 fusions (BICC1, AHCYL1, CREB5, NOL4, NRAP, PAH, POC1B, SH3GLB1, BAIAP2L1, FKBP15, LRRFIP2, and TNS3), FGFR3::TACC3 fusion, and FGFR2 mutations (C382R and Y375C). FGFR2/3-altered iCCA patients were significantly younger (median, 61.0 vs 68.0 years; P = .014), with larger (median, 9.6 vs 6.4 cm; P = .002), well-differentiated (24.0% vs 1.5%; P 2.5 ng/mL (lower PFS), TP53 mutation (lower OS), KRAS mutation (lower OS and DSS), radiotherapy (higher OS), and surgical resection (higher OS, MFS, and DSS). FGFR2/3-altered iCCAs represent a distinct subtype associated with improved DSS, driven by inherent clinicopathologic and co-molecular characteristics rather than FGFR2/3 alteration status alone. Genomic profiling expands the molecular landscape of iCCAs, refines prognostication, and informs patient selection for targeted therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Gastrointestinal and Liver Pathology, Emory University School of Medicine, Atlanta, Georgia.
- Caris Life Sciences, Irving, Texas.
- Department of Pathology, Gastrointestinal and Liver Pathology, Emory University School of Medicine, Atlanta, Georgia; Department of Pathology, Molecular Genetics Pathology, Emory University School of Medicine, Atlanta,…
Zitieren
APA
Hsiao, W. Y., Angara, K., & Mejbel, H. A. (2026). FGFR2/3-Altered Intrahepatic Cholangiocarcinoma: A Distinct Clinicopathologic and Molecular Subtype Associated with Improved Disease-Specific Survival. Modern Pathology, 39(12), 101094. https://doi.org/10.1016/j.modpat.2026.101094
Vancouver
Hsiao WY, Angara K, Mejbel HA. FGFR2/3-Altered Intrahepatic Cholangiocarcinoma: A Distinct Clinicopathologic and Molecular Subtype Associated with Improved Disease-Specific Survival. Modern Pathology. 2026;39(12):101094. doi:10.1016/j.modpat.2026.101094
BibTeX
@article{Hsiao2026,
author = {Hsiao, Wen-Yu and Angara, Kartik and Mejbel, Haider A},
title = {FGFR2/3-Altered Intrahepatic Cholangiocarcinoma: A Distinct Clinicopathologic and Molecular Subtype Associated with Improved Disease-Specific Survival},
journal = {Modern Pathology},
year = {2026},
volume = {39},
number = {12},
pages = {101094},
doi = {10.1016/j.modpat.2026.101094}
}
EUVIMED